The toxicity of the bis-succinyl derivative of the protein antibiotic, neocarzinostatin, was compared with the parent compound, neocarzinostatin (NCS), in rats. The derivative was found to be about two to five fold more active than NCS in vivo. The antitumor activity in rats bearing eleven distinct YOSHIDA hepatoma ascitic cell lines was tested under four possible combinations with regard to sites of drug and tumor cell administration.
We reported previously the preparation and chemical and biological characterization of the bissuccinyl (NaAla 1, N5Lys 20) neocarzinostatin derivative of the antitumor antibiotic, neocarzinostatin (NCS). It was found in comparison with NCS that modification of the two amino groups in NCS did not alter the effect of the drug against cultured cell lines at 0.25 /tg/ml level, but a considerable decrease was observed in antibacterial activity1,2). Furthermore, the stability of the derivative against proteolytic digestion by blood or serum enzymes was enhanced due to succinylation of the free amino groups in NCS3,4). These results prompted an investigation of the potential usefulness of the derivative in vivo.
In the present communication we wish to report the toxicity and antitumor activity of the succinyl derivative of neocarzinostatin in comparison with NCS. Furthermore, the action of the two compounds upon DNA synthesis was also studied with a cultured lymphoblastoid cell line.
Materials and Methods
Succinyl NCS: Bis-succinyl neocarzinostatin (SUC) was prepared as described previously2).
NCS (Lot. T-58) was obtained from Kayaku Antibiotic Research Laboratories, Tokyo, and the same lot was used throughout the investigation. Toxicity: Acute toxicity of SUC and NCS was examined with a single dose of drug given to female Donryu rats (ca. 150 g, five or six rats per group) which had been inoculated intraperitoneally (i.p.) with 106 YOSHIDA sarcoma cells 72 hours prior to the tests. The administration of the drugs was carried out via i.p., or i.v. (tail), at doses of 0.63, 1.25, 2.5, 5, 10 and 20 mg/kg or orally at doses of 5, 10, 50, 100, 250 and 500 mg/kg, respectively.
Cytological observations of the tumor cells were also conducted microscopically at about x 100 after staining with WRIGHT-GIEMSA solution. Antitumor Activity in Rats:
Assays were employed to establish the antitumor spectrum of SUC Antitumor Activity in Mice: The procedures employed were described in a previous publication6) and the assays were carried out by the Drug Research and Development Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md., U.S.A. The strains of mice used for the expriments were BDF1 (male), DCF1 (male) and BDF1 (female), while the tumor lines used were L1210, P388 (both leukemia) and B16 (melanocarcinoma).
Inoculations were made intraperitoneally in all three cases. Cells were obtained (1) by adding 10 ml of a cold HANKS' balanced salt solution to 1 g of non-necrotic tumor (solid mass of B16) and homogenizing followed by filtration with wire gauze and implantation of 0.5 ml, or (2) from the ascitic fluid (L1210 and P388) derived from the tumor-bearing mice with an inoculum size of 105 (L1210) and 106 (P388) cells. The drug was dissolved in saline and administered i.p. once daily at doses of 2.0, 1.0, 0.5, 0.25 and 0.13 mg/kg, respectively for 9 days beginning one day after tumor inoculation. The effect of the drug was measured by the prolongation [on day 20 (L1210), on day 30 (P388), or on day 60 (B16)] of the median survival time (B16 and P388) and mean survival time (L1210) over control. The data are expressed as percent of test/control.
Inhibition of DNA Synthesis: The effect of SUC and NCS on DNA synthesis was compared in vitro. Cells used were a lymphoblastoid cell line, P3HR-1, which originated from human Burkitt's lymphoma, and were maintained in floating culture in RPMI-1640 (Gibco Inc., Grand Island, N.Y.) with 10 % fetal calf serum1). An initial cell density of 2 x 105 cells/ml were used. 6-[3H] Thymidine, (specific activity, 1.40 1tCi/1t mole; Daiichi Pure Chemical Inc. Co., Tokyo) was added at a final concentration of 0.3 /iCi/ml to the media. Incorporation of tritium-labeled thymidine into DNA was studied in the presence and absence of NCS or SUC. The incorporation into DNA was terminated by addition of 30% trichloroacetic acid to a final concentration of 5 % and the trichloroacetic acid precipitable samples were filtered on glass-fiber filters (GB-100, Toyo Scientific Inc. Co., Tokyo) and washed with 5 % trichloroacetic acid followed by washing with cold ethanol and ethyl ether. Radiolabel on the filter pads was measured by liquid scintillation counting.
Results

Toxicity
The doses of NCS and SUC given i.p. and the percent survival-days for rats are shown in Fig. 1 ; the median LD50 and average survival days are summarized in Table 1 . When a dose of 5 mg/kg of the derivative was given i.p., edema in the intestines and shrinkage of the spleen were observed. Cytolo- to the toxicity of both drugs (Fig. 1) . The death of rat due to the toxicity of NCS or SUC occurred even after 30 days following administration of the drug.
Antitumor Activity
The results with SUC and NCS are summarized in Tables 2 and 3 Table 2 . In the case of AH41C, the effect of SUC was found to be positive cytologically but prolongation of the life-span was moderate (50% of rats showed more than 200% increase in the expected life-span); a finding which is similar to that observed with NCS. In rats with AH-109A tumor, SUC possessed an antitumor activity greater than NCS; thus more than 50% of the rats exhibited 200% prolongation of the expected life span.
As seen in Table 2 The effect of SUC on three different tumor systems in mice is shown in Table 3 . The derivative possessed activity on L1210, P388 and the B16 melanocarcinoma which was comparable to NCS7). In fact, three complete cures out of six mice injected with the P388 strain were seen. Death due to the toxic effect of the drug was not observed at the dose levels used.
Effect on DNA Synthesis
As shown in Fig. 2A and 2B the inhibitory effect of NCS and SUC on DNA synthesis as judged by the rate of thymidine incorporation was almost the same.
Discussion
The results of the experiments on DNA synthesis in mammalian cells in culture show that both SUC and NCS exhibit the same inhibitory activity to the same extent (at 1,4,10 ,ug/ ml) (Fig. 2. A, B) . On the other hand, a considerable difference was observed in their activity in vivo (Table 1 , Fig. 1. A, B) . Namely, in comparison with NCS there was about a two fold increase in the toxicity and five fold increase in the antitumor activity of SUC ( The results shown in Table 2 indicate that either NCS or SUC is most effective when the drug is given very close to or in situ with the tumor cells (i.p./i.p.).
We interpret this finding to mean that NCS or SUC has a very short half-life in vivo, because of the instability due to both proteolytic degradation3,4) and extremely rapid renal clearance8).
When NCS or SUC is given at site remote from target tumor site (eg. i.p./i.v. or i.v./i.p.), the drug is inactivated and also excreted into urine before reaching the tumor site, thus it exhibited little effect. When the drug is given i.v. and tumors inoculated i.v., the extremely short half-life of the drug in plasma3'8,9) also resulted little effect because most of the AH-tumor cells would manage to escape from the susceptible phase of the cell cycle (S-phase and G-2) thus unaffected.
The present results indicate, therefore, that NCS and also SUC should be more effective, in view of its short half-life, when administered directly into the tumor or very near to the tumor cells in order to facilitate direct contact.
The results also reveal that SUC possessed a similar antitumor spectrum to NCS which may be due to similar distribution in vivo because of similar physicochemical properties and molecular weight. The strongly hydrophilic nature of NCS10) is not changed by the addition of two succinyl residues which are also hydrophilic.
The observation that both NCS and SUC inhibit DNA synthesis in a lymphoblastoid cell line suggests to us that other biological activities (eg. DNA degradation, inhibition of mitosis) exhibited by SUC may also be comparable to those found in studies with NCS using HeLa cells11). By contrast, however, the altered pharmacokinetic properties, namely increased in vitro stability4) and also enhanced in vivo activity of the modified derivative have been clarified.
Based on these results, more advantageous dose regimen, different from that of NCS, for SUC should be designed in its clinical applications.
